

|              |   |
|--------------|---|
| <b>DATE:</b> | 8 December 2025   |
| <b>TO:</b>   | All Pathologists  |
| <b>FROM:</b> | Molecular Pathology Program, Alberta Precision Laboratories |
| <b>RE:</b>   | <b>Discontinuation of Cyclin D1 and BCL2 PCR Testing</b>    |

---

## PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

---

### Key Message

- Effective December 9, 2025 PCR based testing for the cyclin D1 (AKA BCL-1) and BCL-2 translocation will be discontinued.
- **This applies ONLY to PCR testing.** Testing for these translocations by FISH will continue to be available and will be the recommended primary testing modality

### Background

- Recurrent chromosomal translocations involving the cyclin D1 gene locus t(11;14), BCL-2 t(14;18) and the IgH promoter/enhancer region are the primary driver events for mantle cell and follicular lymphoma, respectively
- Testing for these alterations can be performed via fluorescent in situ hybridization (FISH) and historically by targeted PCR testing.
- PCR testing cannot detect all such translocations and has a 50-60% sensitivity for said alterations, which increases the chance of false negative results and missed diagnoses
- Decreasing testing volumes, combined with improved turn around times for Cyclin D1 and BCL2 FISH testing has rendered PCR testing obsolete in the context of the limited assay sensitivity.

### How this will impact you

- PCR testing for these translocations will be discontinued and the order set removed from EPIC
- Pathologists requiring testing for Cyclin D1 or BCL-2 translocations will be required to order FISH testing for these genes instead

### Action Required

- **Pathologists:** Switch to ordering CG-CCND1 / CG-t(11;14), or CG-t(14;18) in EPIC for cyclin D1 or BCL-2 translocation testing, respectively.

**Effective**      **December 9, 2025**

### Questions/Concerns

- Adrian Box, Provincial Medical/Scientific Director, Molecular Pathology [Adrian.box@albertaprecisionlabs.ca](mailto:Adrian.box@albertaprecisionlabs.ca)
- Dr. Cheryl Mather, Medical Lead, Molecular Pathology North  
[Cheryl.mather@albertaprecisionlabs.ca](mailto:Cheryl.mather@albertaprecisionlabs.ca)

### Approved by

- Dr. Adrian Box, Medical/Scientific Director, Molecular Pathology Program
- Christine Franz, Operations Director, Genetics & Genomics / Molecular Pathology
- Dr. Carolyn O'Hara, Chief Medical Laboratory Officer (Interim), Alberta Precision Laboratories